Harnessing the Innate Properties of Novel E3 Ligase Trim21 for the Development of Treatments for Neurodegenerative Diseases
- Why TRIM 21 is ideally suited to selectively degrading protein aggregates which underpin so many neurodegenerative diseases
- TrimTech’s approach to validating targets and TRIM21’s role in degrading these targets with a range of modalities
- TrimTech’s strategies and progress developing therapeutic degraders known as a TRIMTACTM or TRIMGLUETM for neurodegenerative and inflammatory diseases